FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA-483 Response Can Influence Future Agency Action: Post

NSF consultants report on a webinar discussing the best practices in responding to inspection observations in a form FDA-483.

latest-news-card-1
Human Drugs

Objectionable Conditions in Dr. Adnan Dahdul's Clinical Trial

FDA warns Springfield, MA-based physician Adnan Dahdul about Bioresearch Monitoring violations in his conduct of a clinical investigation.

latest-news-card-1
Human Drugs

Info Request Period on AI Use in Early Trials Extended

FDA extends by 30 days the comment period on a request for information entitled AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program."...

latest-news-card-1
Biologics

Lilly Loading Up Vaccines Plate for Former CBER Head Marks

Eli Lilly says it is acquiring three vaccine developers in deals worth up to $3.8 billion combined, expanding its push into infectious disease prevent...

latest-news-card-1
Human Drugs

India OTC Drug Manufacturer Slapped With Form-483

FDA cites Dabur India Limited for significant manufacturing and data integrity violations at an over-the-counter drug manufacturing facility in India.

latest-news-card-1
Medical Devices

Low PCCP Use Could be Missed Opportunity: Study

Researchers say manufacturers could make better use of predetermined change control plans for AI-enabled medical devices.

latest-news-card-1
Medical Devices

FDA, Federal Prosecutors Take Tougher Stance on Safety Reporting: Analysis

A Cooley legal analysis notes that FDA and federal prosecutors are signaling a tougher stance on failures to report patient safety issues to regulator...

latest-news-card-1

Seismic Loper Bright Impact Not Yet Seen: Attorneys

A Yale Journal on Regulation article from the Yale Law School Solomon Center for Health Law & Policy examines how the Supreme Courts Loper Bright deci...

latest-news-card-1
Human Drugs

Alchymars ICM SM Inspection Issues

FDA warns Indias Alchymars ICM SM Private Limited about CGMP deviations in its production of active pharmaceutical ingredients.

latest-news-card-1
Human Drugs

CGMP Issues at Japans Sato Pharmaceutical Co.

FDA warns Japans Sato Pharmaceutical Co. about CGMP violations in its production of finished over-the-counter drugs.